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Summary Current neuroscience suggests that although short-term memory
difficulties frequently occur immediately after electroconvulsive therapy (ECT),
longer-term problems are less common. However, gaps in our knowledge remain
regarding longer-term cognitive problems after ECT, including memory function.
Some of these relate to the complexities surrounding cognitive testing and
interpretation of test results. An important question in clinical decision-making is
why, despite current evidence suggesting long-term memory problems are less
frequent, some patients still report subjective memory difficulties. To further advance
clinical practice and the neuroscience surrounding post-ECT cognitive function,
assessment of cognitive function, possibly including neuropsychological testing,
should potentially become more routine as part of clinical practice.
Declaration of interest None
Measuring treatment response after depression is often not
entirely straightforward in clinical practice. What matters to
clinicians might not always perfectly align with what is
important to their patients. For example, the DSM-5 lists a
combination of physical, cognitive, affective and behavioural
diagnostic criteria representing major depressive disorder
(MDD).1 For patients with MDD, subjectively, fatigue is
sometimes the most disconcerting symptom, whereas for
others it might be impaired concentration or the persistent
feelings of sadness and hopelessness, resulting in a range
of subtly different presentations. Similarly, a wide range of
effective treatments for MDD are now available, depending
on patients’ clinical presentation. Treatments range from
pharmacological approaches, talking therapies and physical
exercise, to electroconvulsive therapy (ECT) or a combin-
ation of these, among others. Treatment approaches all
have different levels of efficacy, potential side-effects, and
accordingly their acceptability to patients with MDD varies.
A recent retrospective study found that patients were
generally satisfied with ECT as a safe and effective treatment
for depression.2 Nevertheless, one of the suggested adverse
side-effects of ECT concerns possible memory problems.
Whether ECT can have a deleterious effect on memory pre-
sents an important question for both the clinician and
patient when discussing treatment options. An appraisal of
the current neuroscience knowledge on memory and ECT
can provide some guidance to further inform clinical
decision-making, including addressing patients’ concerns
regarding treatment choice. Lezak et al, reviewing neuro-
psychology and other neuroscience findings concerning
ECT and memory, conclude that memory difficulties imme-
diately post-ECT can be present in some patients, but that it
is less common beyond this period, even in patients who
have had longer-term treatment.3 Similarly, Kirov et al con-
clude that long-term memory effects are rare and that ECT
appears to be safe as regards adverse neuropsychological
outcomes.4 Furthermore, a recently published, large cohort
study found that the risk of developing dementia in patients
previously treated with ECT was not significant.5 These find-
ings might reassure clinicians, but what about patients’
views? Understanding patients’ preferences and concerns
as regards treatment choice is an important aspect of clinical
decision-making and ultimately for determining overall
treatment response.
Memory complaints post-ECT
Vann Jones and McCollum6 report the findings from their
systematic review of ECT and subjective memory
complaints. Although there were methodological limitations
to some of the included studies, which made definitive con-
clusions difficult, their review does suggest that generally
subjective memory ratings improve over time, and that
ultrabrief-pulse ECT potentially has less side-effects.
Interestingly, another study not included in their review
reported that although cognitive function appears to be
largely unchanged in many (but not all) areas of neuro-
psychological functioning, improved depression long-term
post-ECT appears to be associated with improvement in
some cognitive functions.7 Vann Jones and McCollum’s
review raises some interesting questions for clinical practice
and neuroscience. In particular, if the above (and other)
findings from the research literature is correct in concluding
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that ECT is safe as regards memory functions, why is it that
a number of patients consistently continue to report longer-
term subjective memory difficulties after ECT?
Addressing the above question is potentially of consid-
erable relevance not only to patients, but also clinicians.
For example, from a policy and practice perspective there
is an acknowledgement of the importance of considering
cognition as part of ECT service delivery. The Royal
College of Psychiatrists Statement on Electroconvulsive
Therapy advises that cognitive functioning should be
assessed before ECT and monitored after every three or
four ECTs, and also after the final ECT.8 Furthermore, the
Statement indicates that in addition to orientation being
assessed after each ECT, retrograde amnesia, new learning
and subjective memory complaints should be tested more
than 24 h post-ECT. However, exactly how to perform test-
ing of these functions is not specified. Interestingly, looking
at some current National Health Service ECT policies fails to
identify a consistent and clearly defined approach to asses-
sing cognition in ECT services. To summarise, although
the relevance of assessing cognition after ECT is clearly
acknowledged, how to do this remains less clear. At present,
there is not a straightforward answer doctors can give to
patients receiving ECT, if they ask exactly how their memory
functions will be monitored.
Assessing cognition post-ECT
Assessment of cognition can be performed at different levels,
providing objective or subjective data. Patients can be asked
about their own views on their cognitive functioning, which
provide subjective data. Objective testing can be performed
at the bedside, or can constitute formal neuropsychological
testing. In the latter case, the patient’s results are compared
against standardised norms as well as their own predicted
premorbid level of functioning. Patient effort is also mea-
sured to identify any underperformance that might influence
the interpretation of test results. Cognitive domains
assessed generally include information processing, language
functions, new learning and retention, construction, visual–
spatial abilities and executive control functions, among sev-
eral others. Kolar suggests that neuropsychological testing
should be an integral part of ECT service provision.9 In
ECT services, testing will most likely focus on cognitive
domains such as new learning and retention, as well as infor-
mation processing. Although the assessment of cognitive
functions appears straightforward enough, interpretation of
the results is not. This may be one of the reasons why
wider implementation of cognitive assessment post-ECT
has not occurred.
Returning to the relevance of diagnostic criteria as out-
lined at the beginning of this editorial provides a good
example of some of the complexities surrounding post-ECT
cognitive assessment. Cognitive symptoms of MDD, such as
poor concentration, can be affected by some of the other fea-
tures of the disorder. For example, insomnia can adversely
affect concentration, which will have a negative downstream
effect on memory (new learning and retention). The same
applies to fatigue. In terms of the statistical interpretation
of neuropsychological test results, one example would be
that consideration should be given to the possibility that
when compared with standardised norms, depressed patients
may already (before ECT) be underperforming, or even be
near floor level (a score that is too low to reliably identify
any further decline in performance). This is one of the rea-
sons why the individual patient’s neuropsychological profile
ideally should be interpreted against their own predicted pre-
morbid level of cognitive function by using, for example,
demographic data or formal tests of premorbid intellectual
function. Other issues related to interpretation of test results
concerns for example determining what constitutes a reliable
clinical change during serial testing, or identifying what
represents an impairment versus a below average perform-
ance of a given cognitive function in a test protocol.
There are also non-cognitive factors to consider when
interpreting data. Particularly relevant to Vann Jones and
McCollum’s study would be the effect of patients’ self-
awareness (or ‘insight’) on their subjective judgements of
memory function. Problems in this area can influence how
patients rate their memory performance and result in very
different scores from actual objective test performance.
For example, a small study looking at repeated neuropsycho-
logical testing about 3 weeks after ECT found objective as
well as subjective memory difficulties to be present, but
the authors cautioned that subjective post-ECT reports of
memory problems may be influenced also by problems of
awareness, questioning their reliability.10 Perhaps if routine
standard cognitive assessment were available in ECT ser-
vices, patients could be reassured that in addition to their
own ‘report back’ opportunities to identify their concerns
about memory problems with their doctor, their cognitive
functions (including memory) would be closely monitored
for objective change.
Remaining questions
Although current research appears to indicate that ECT in
most patients does not appear to have lasting adverse effects
on memory, we can, of course, not be entirely sure that this
is always the case for all patients. For example, prospective
studies that look at ECT effects on cognition, where baseline
neuropsychological testing including consideration of pre-
morbid intellectual ability is included and compared with a
control group, could help to further advance our understand-
ing of the cognitive neuroscience surrounding this topic.
However, of particular relevance to Vann Jones and
McCollum’s interesting review, to help address patients’
concerns expressed through their subjective reports of
ongoing memory difficulties, the following could possibly
be helpful to think about. Future research in the area may
wish to consider more closely which specific non-cognitive
factors, including self-awareness, might account for a dis-
crepancy between actual and reported cognitive impairment.
For example, a recent study of patients with acquired brain
injury found that most of the variance between actual and
perceived cognitive impairment was explained by affective
factors such as anxiety or low mood.11 Conversely, it may
be helpful to also look more closely at which specific symp-
tom(s) of MDD improve post-ECT. As an example, one inter-
esting hypothesis to test would be to determine how much of
2
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improvement in depression can be accounted for (or not) by
a specific improvement in patients’ ability to think or con-
centrate post-ECT.
As regards clinical practice, one of the possible
implications from Vann Jones and McCollum’s study is
that there may be a need to consider if it is necessary to
determine recommended standards of cognitive testing or
clearer guidance on testing for UK ECT services. It may, of
course transpire, that routine standardised cognitive testing
of all patients receiving ECT would possibly be unhelpful or
even harmful, raising anxiety-provoking questions in
patients’ minds that were not there before. However, if stan-
dardised testing were deemed necessary to implement, close
consideration might need to be given to factors such as
which cognitive functions are most relevant to test in the
ECT situation, the length of such assessments and, closely
related to the latter, what type of assessment (bedside,
formal neuropsychological testing or a hybrid approach),
among other questions. To conclude, several recent
papers illustrate the essence of some of these questions.
Although the Montreal Cognitive Assessment12 is considered
to be useful in monitoring cognitive function after ECT,13 on
the other hand, cognitive assessment after ECT is also
presently thought to not be comprehensive enough,
especially if limited to bedside testing only.9 As with many
of the questions surrounding the clinical practice and neuro-
science of ECT, this is not an easy one to provide a definitive
answer to.
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